Published in Clin Cancer Res on January 01, 2008
Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. | NCT03392740
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci (2012) 1.30
Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Womens Health (Larchmt) (2009) 1.12
Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One (2010) 1.03
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel) (2010) 0.97
Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol (2010) 0.96
Cancer, physical activity, and exercise. Compr Physiol (2012) 0.94
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem (2013) 0.91
Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol (2013) 0.90
Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2013) 0.86
Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models. BMC Med Res Methodol (2012) 0.86
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol (2010) 0.86
A mouse model of radiation-induced cardiomyopathy. Int J Cardiol (2012) 0.85
Effects of exercise intervention in breast cancer survivors: a meta-analysis of 33 randomized controlled trails. Onco Targets Ther (2016) 0.84
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Dose Distribution in the Heart and Cardiac Chambers Following 4-field Radiation Therapy of Breast Cancer: a Retrospective Study. Breast Cancer (Auckl) (2013) 0.82
Breast cancer survivorship issues. Hematol Oncol Clin North Am (2013) 0.82
Unintended cardiac irradiation during left-sided breast cancer radiotherapy. Br J Radiol (2013) 0.82
Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist (2013) 0.82
Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. Pharmacoepidemiol Drug Saf (2012) 0.80
Comparison of radiation dose to the left anterior descending artery by whole and partial breast irradiation in breast cancer patients. J Contemp Brachytherapy (2015) 0.80
Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer (2013) 0.80
Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One (2014) 0.80
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem (2015) 0.79
Automatic Coronary Artery Calcium Scoring on Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association with Traditional Cardiovascular Risk Factors. PLoS One (2016) 0.77
Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. Herz (2011) 0.77
Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control (2016) 0.77
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. J Med Chem (2015) 0.77
The utility of cardiac stress testing for detection of cardiovascular disease in breast cancer survivors: a systematic review. Int J Womens Health (2015) 0.76
Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk. Cancer Med (2014) 0.76
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients. BMC Cancer (2016) 0.76
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus (2015) 0.76
Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support Care Cancer (2014) 0.76
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol (2016) 0.75
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Oncologist (2016) 0.75
Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open (2015) 0.75
Cancer and Cardiovascular Disease: The Complex Labyrinth. J Oncol (2015) 0.75
Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget (2016) 0.75
Cardiotoxicity Following Cancer Treatment. Ulster Med J (2017) 0.75
Radiotherapy and anthracyclines - cardiovascular toxicity. Contemp Oncol (Pozn) (2014) 0.75
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β. Bioorg Med Chem (2016) 0.75
Coronary ectasia in a man on breast cancer therapy presenting with acute coronary syndrome. Avicenna J Med (2016) 0.75
Tako-tsubo cardiomyopathy in a 92-year old woman. Clin Med Insights Case Rep (2011) 0.75
11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. J Cancer Res Clin Oncol (2016) 0.75
Coronary artery calcium in breast cancer survivors after radiation therapy. Int J Cardiovasc Imaging (2017) 0.75
Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat (2017) 0.75
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clin Transl Oncol (2017) 0.75
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol (2006) 3.62
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93
Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst (2004) 2.72
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res (2002) 1.82
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther (2007) 1.68
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (2011) 1.56
The influence of a gene expression profile on breast cancer decisions. J Surg Oncol (2009) 1.52
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol (2007) 1.50
Locally advanced and inflammatory breast cancer. J Clin Oncol (2008) 1.44
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol (2005) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med (2010) 1.40
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology (2007) 1.24
ASCO's approach to a learning health care system in oncology. J Oncol Pract (2013) 1.22
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat (2010) 1.08
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer (2010) 1.08
Therapeutic strategies for triple-negative breast cancer. Cancer J (2008) 1.05
Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol (2011) 1.05
Clinical aspects of inflammatory breast cancer. Breast Dis (2006) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat (2011) 1.01
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol (2005) 1.00
Aromatase inhibitors--a triumph of translational oncology. N Engl J Med (2005) 1.00
Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep (2007) 0.98
Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol (2003) 0.98
Drug discount program. JAMA (2013) 0.97
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res (2004) 0.95
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res (2005) 0.94
The epothilones: translating from the laboratory to the clinic. Clin Cancer Res (2008) 0.93
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res (2004) 0.92
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.92
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology (2007) 0.88
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist (2012) 0.87
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol (2006) 0.87
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs (2006) 0.86
Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer (2005) 0.86
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat (2006) 0.86
A step in the right direction. J Clin Oncol (2006) 0.85
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer (2006) 0.85
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res (2006) 0.84
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer (2012) 0.83
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer (2011) 0.83
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs (2007) 0.83
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
CA 125 elevation in breast cancer: a case report and review of the literature. Breast J (2004) 0.82
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer (2014) 0.82
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med (2013) 0.82
Primary systemic chemotherapy for inflammatory breast cancer. Cancer (2010) 0.82
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med (2013) 0.81
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat (2013) 0.81
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs (2013) 0.81
Contralateral breast cancer: where does it all begin? J Clin Oncol (2005) 0.80
Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs (2008) 0.80
The heart of the matter. J Clin Oncol (2007) 0.80
Cardiac dysfunction after cancer treatment. Tex Heart Inst J (2011) 0.80
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol (2011) 0.79
Pertuzumab for the treatment of breast cancer. Cancer Invest (2014) 0.79
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol (2002) 0.79
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther (2013) 0.78
Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs (2006) 0.78
Treatment of HER2-positive metastatic breast cancer. N Engl J Med (2015) 0.77
Treatment and cost implications of pertuzumab. Am J Manag Care (2012) 0.77
Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs (2012) 0.76
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin Breast Cancer (2005) 0.76
Oophorectomy in carriers of BRCA mutations. N Engl J Med (2002) 0.75
Pertuzumab: increasing the options. Oncology (Williston Park) (2014) 0.75
First, do no harm. Onkologie (2008) 0.75
Meta-analysis: should it be more than the sum of its parts? J Natl Cancer Inst (2010) 0.75
Avastin withdrawal symptoms. Expert Opin Pharmacother (2012) 0.75
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clin Breast Cancer (2004) 0.75